Henry Schein, Inc.
HSIC Healthcare Medical Distribution
Henry Schein, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.2 billion, up 4.03% from fiscal 2024. In the quarter to June 2026, revenue grew 6.73%, EPS grew 16.9%, free cash flow grew 140.9% and total debt rose 15.2%, each against the same quarter a year earlier. Member of the S&P 500; insiders bought in the last twelve months.
Follow HSIC
Henry Schein, Inc. (HSIC) EBITDA
Henry Schein, Inc.'s EBITDA for fiscal 2025 was $964.0M, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $1.0B. Over the past ten years it has ranged from $721.0M (fiscal 2020) to $1.1B (fiscal 2021); the current reading is higher than 91% of that period. Henry Schein, Inc. ranks 4th of 10 Medical Distribution companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $964.0M | 3.66% |
| FY2024 | $930.0M | 4.49% |
| FY2023 | $890.0M | (7.19%) |
| FY2022 | $959.0M | (9.70%) |
| FY2021 | $1.1B | 47.30% |
| FY2020 | $721.0M | (20.17%) |
| FY2019 | $903.2M | 21.36% |
| FY2018 | $744.2M | (7.39%) |
| FY2017 | $803.6M | (14.63%) |
| FY2016 | $941.4M | 5.40% |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | $255.0M | (3.04%) |
| Mar 2026 | $263.0M | 7.35% |
| Dec 2025 | $245.0M | 0.82% |
| Sep 2025 | $243.0M | 7.05% |
| 42 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| MCK McKesson Corporation compare | $7.3B |
| COR Cencora, Inc. compare | $4.1B |
| CAH Cardinal Health, Inc. compare | $3.6B |
| HSIC Henry Schein, Inc. | $1.0B |
| ACH Accendra Health, Inc. compare | $285.4M |
| COSM Cosmos Health Inc. compare | −$16.9M |
| FOCL FocalTherics compare | −$25.3M |
| AHG Akso Health Group Sponsored ADR compare | −$30.3M |
| HKPD Cellyan Biotechnology Co., Ltd compare | — |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on HSIC
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement